{"transactions":[{"id":695488,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":26200,"kind":"organization","name":"DEFJ, LLC","position":1,"cik":"0002147448","reported_name":"DEFJ, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":2,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2026-08-05T20:05:41.000Z","date":"2026-08-03","kind":"exercise","planned":false,"acquired":false,"shares":202.0582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2020582},"source":{"system":"sec-edgar","filing":"0001104659-26-091078","document":"tm2622262-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1297567/000110465926091078/tm2622262-2_4seq1.xml","form_type":"4"}},{"id":695487,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":26200,"kind":"organization","name":"DEFJ, LLC","position":1,"cik":"0002147448","reported_name":"DEFJ, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":2,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2026-08-05T20:05:41.000Z","date":"2026-08-03","kind":"exercise","planned":false,"acquired":false,"shares":1181.3859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Includes 28.4291 shares of Series A Non-Voting Convertible Preferred Stock previously issued to DEFJ as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11813859},"source":{"system":"sec-edgar","filing":"0001104659-26-091078","document":"tm2622262-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1297567/000110465926091078/tm2622262-2_4seq1.xml","form_type":"4"}},{"id":695486,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":26200,"kind":"organization","name":"DEFJ, LLC","position":1,"cik":"0002147448","reported_name":"DEFJ, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":2,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-05T20:05:41.000Z","date":"2026-08-03","kind":"exercise","planned":false,"acquired":true,"shares":2020582,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":14134481,"source":{"system":"sec-edgar","filing":"0001104659-26-091078","document":"tm2622262-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1297567/000110465926091078/tm2622262-2_4seq1.xml","form_type":"4"}},{"id":695485,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":26200,"kind":"organization","name":"DEFJ, LLC","position":1,"cik":"0002147448","reported_name":"DEFJ, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":2,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-05T20:05:41.000Z","date":"2026-08-03","kind":"exercise","planned":false,"acquired":true,"shares":11813859,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Issuer's (i) Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A Non-Voting Convertible Preferred Stock\") and (ii) Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series B Non-Voting Convertible Preferred Stock\"), are convertible at any time into shares of Common Stock, par value $0.0001 per share (\"Common Stock\"), with each share of Series A Non-Voting Convertible Preferred Stock or Series B Non-Voting Convertible Preferred Stock, as applicable, convertible into 10,000 shares of Common Stock. Neither the shares of Series A Non-Voting Convertible Preferred Stock nor the shares of Series B Non-Voting Convertible Preferred Stock have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2026, DEFJ, LLC (\"DEFJ\") (i) submitted a notice to the Issuer providing that it waived the Beneficial Ownership Limitation (as defined in the Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (\"Certificate of Designation\")) set forth in Section 6.3.3 of the Certificate of Designation, effective as of August 3, 2026, and (ii) submitted an irrevocable conversion notice to the Issuer providing that DEFJ converts 1,181.3859 shares of Series A Non-Voting Convertible Preferred Stock into 11,813,859 shares of Common Stock and 202.0582 shares of Series B Non-Voting Convertible Preferred Stock into 2,020,582 shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"DEFJ, a Delaware limited liability company, is a direct, wholly owned subsidiary of Conjoint Inc., a Delaware corporation, which is a direct, wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company, which is a direct, wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an admission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":12113899,"source":{"system":"sec-edgar","filing":"0001104659-26-091078","document":"tm2622262-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297567/000110465926091078/tm2622262-2_4seq1.xml","form_type":"4"}},{"id":988958,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":72594,"kind":"person","name":"Sealbond Ltd","position":1,"cik":"0002040446","reported_name":"Sealbond Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":72595,"kind":"person","name":"Conjoint Inc.","position":2,"cik":"0002061651","reported_name":"Conjoint Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":3,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A-1 Preferred Stock","published_at":"2025-11-25T17:39:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":284.2638,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Conjoint Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares are held directly by Conjoint Inc., a Delaware corporation (\"Conjoint\"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company (\"Honglad\"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company (\"ENSO Resources\"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2842638},"source":{"system":"sec-edgar","filing":"0001104659-25-116066","document":"tm2532101-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2040446/000110465925116066/tm2532101-2_4seq1.xml","form_type":"4"}},{"id":988957,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":72594,"kind":"person","name":"Sealbond Ltd","position":1,"cik":"0002040446","reported_name":"Sealbond Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":72595,"kind":"person","name":"Conjoint Inc.","position":2,"cik":"0002061651","reported_name":"Conjoint Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":3,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Preferred Stock","published_at":"2025-11-25T17:39:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":2161.095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"Includes 52.7096 shares of Series A Preferred Stock previously issued to Sealbond as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Sealbond Limited, a British Virgin Islands limited company (\"Sealbond\"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company (\"Kamfull\"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company (\"Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21610950},"source":{"system":"sec-edgar","filing":"0001104659-25-116066","document":"tm2532101-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040446/000110465925116066/tm2532101-2_4seq1.xml","form_type":"4"}},{"id":988956,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":72594,"kind":"person","name":"Sealbond Ltd","position":1,"cik":"0002040446","reported_name":"Sealbond Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":72595,"kind":"person","name":"Conjoint Inc.","position":2,"cik":"0002061651","reported_name":"Conjoint Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":3,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-25T17:39:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":2842638,"ownership":{"direct":false,"nature":"By Conjoint Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares are held directly by Conjoint Inc., a Delaware corporation (\"Conjoint\"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company (\"Honglad\"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company (\"ENSO Resources\"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":2842638,"source":{"system":"sec-edgar","filing":"0001104659-25-116066","document":"tm2532101-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040446/000110465925116066/tm2532101-2_4seq1.xml","form_type":"4"}},{"id":988955,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":72594,"kind":"person","name":"Sealbond Ltd","position":1,"cik":"0002040446","reported_name":"Sealbond Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":72595,"kind":"person","name":"Conjoint Inc.","position":2,"cik":"0002061651","reported_name":"Conjoint Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":3,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-25T17:39:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":21610950,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Sealbond Limited, a British Virgin Islands limited company (\"Sealbond\"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company (\"Kamfull\"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company (\"Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":21822333,"source":{"system":"sec-edgar","filing":"0001104659-25-116066","document":"tm2532101-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040446/000110465925116066/tm2532101-2_4seq1.xml","form_type":"4"}},{"id":1203913,"issuer":{"id":6845,"kind":"organization","name":"Dogwood Therapeutics, Inc."},"owners":[{"id":26201,"kind":"organization","name":"CK Life Sciences Intl (Holdings) Inc","position":1,"cik":"0001297567","reported_name":"CK Life Sciences Intl (Holdings) Inc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A-1 Preferred Stock","published_at":"2025-03-18T01:07:18.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":284.2638,"price":7.01,"value":1992.689238,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 12, 2025, Conjoint entered into a Debt Exchange and Cancellation Agreement with the Issuer pursuant to which $19,500,000 in principal amount of all loans made to the Issuer under a Loan Agreement, dated October 7, 2024 (the \"Loan Agreement\"), between Conjoint and the Issuer, along with accrued interest through March 12, 2025 (as of such date, an aggregate of $19,926,891), was deemed repaid and all of the Issuer's obligations under the Loan Agreement with respect to the principal amount and accrued interest was satisfied in full and cancelled in exchange for 284.2638 shares of Series A-1 Preferred Stock, based on a price per underlying share of Common Stock of $7.01. This transaction involved an acquisition of shares in connection with a debt previously contracted."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 12, 2025, Conjoint entered into a Debt Exchange and Cancellation Agreement with the Issuer pursuant to which $19,500,000 in principal amount of all loans made to the Issuer under a Loan Agreement, dated October 7, 2024 (the \"Loan Agreement\"), between Conjoint and the Issuer, along with accrued interest through March 12, 2025 (as of such date, an aggregate of $19,926,891), was deemed repaid and all of the Issuer's obligations under the Loan Agreement with respect to the principal amount and accrued interest was satisfied in full and cancelled in exchange for 284.2638 shares of Series A-1 Preferred Stock, based on a price per underlying share of Common Stock of $7.01. This transaction involved an acquisition of shares in connection with a debt previously contracted."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), into shares of the Issuer's Common Stock, par value $0.0001 per share (\"Common Stock\"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held directly by Conjoint Inc., a Delaware corporation (\"Conjoint\"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company (\"Honglad\"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company (\"ENSO Resources\"). ENSO Resources is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability (\"CKLS\"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":284.2638,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2842638},"source":{"system":"sec-edgar","filing":"0001104659-25-024577","document":"tm259598-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465925024577/tm259598-1_4seq1.xml","form_type":"4"}}]}